<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04585776</url>
  </required_header>
  <id_info>
    <org_study_id>17601</org_study_id>
    <secondary_id>I8B-MC-ITSZ</secondary_id>
    <nct_id>NCT04585776</nct_id>
  </id_info>
  <brief_title>A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes</brief_title>
  <official_title>An Exploratory Study Assessing Time in Target Glucose Range Using a New Titration Scheme of LY900014 and Insulin Degludec in Patients With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, participants with type 1 diabetes (T1D) will take the study drug LY900014 and&#xD;
      insulin degludec. The reason for this study is to evaluate the amount of time with glucose&#xD;
      values within target range.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 30, 2020</start_date>
  <completion_date type="Actual">May 27, 2021</completion_date>
  <primary_completion_date type="Actual">May 27, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Time with Sensor Glucose Values Between 70 and 180 milligrams per deciliter (mg/dL) with Continuous Glucose Monitoring (CGM)</measure>
    <time_frame>Day 36 to Day 45</time_frame>
    <description>Percentage of Time with Sensor Glucose Values Between 70 and 180 mg/dL (both inclusive) with CGM</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin to Carbohydrate Ratio (ICR)</measure>
    <time_frame>Day 45</time_frame>
    <description>ICR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prandial: Total Daily Dose (TDD) Ratio</measure>
    <time_frame>Day 36 to Day 45</time_frame>
    <description>Prandial: TDD Ratio</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>LY900014 + Insulin Degludec</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY9000014 and insulin degludec given subcutaneously (SC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY900014</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY900014 + Insulin Degludec</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Degludec</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY900014 + Insulin Degludec</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must have type 1 diabetes and have been treated with insulin therapy for&#xD;
             at least 1 year&#xD;
&#xD;
          -  Participants must be using Continuous Glucose Monitoring (CGM) with total CGM use â‰¥ 2&#xD;
             months in the prior 6 months&#xD;
&#xD;
          -  Participants must have been on the same type of short acting insulin (Humalog U-100,&#xD;
             Novolog, Admelog, or Apidra) for at least 30 days prior to screening&#xD;
&#xD;
          -  Participants must have been treated with long-acting insulin degludec U-100 for at&#xD;
             least 30 days prior to screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants must not have had more than 1 emergency room visit or hospitalization due&#xD;
             to poor glucose control within 6 months before screening&#xD;
&#xD;
          -  Participants must not have had more than 1 episode of severe hypoglycemia within the&#xD;
             last 90 days prior to screening&#xD;
&#xD;
          -  Participants must not be taking certain diabetes medications that are not allowed for&#xD;
             study participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Atlanta Diabetes Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa Diabetes and Endocrinology Research Center</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HealthPartners Institute dba International Diabetes Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/32HuxMAefU6YDbyMk6SNjR</url>
    <description>A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes.</description>
  </link>
  <verification_date>June 15, 2021</verification_date>
  <study_first_submitted>October 8, 2020</study_first_submitted>
  <study_first_submitted_qc>October 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

